Skip to Content

Brokerages have given Globus Medical, Inc. (NYSE:GMED) an average recommendation of “Moderate Buy.”

Brokerages have given Globus Medical, Inc. (NYSE:GMED) an average recommendation of “Moderate Buy.”

According to Bloomberg, the eleven analysts currently covering Globus Medical, Inc. (NYSE: GMED) have given the stock an average rating of “Moderate Buy,” indicating that they believe investors should purchase the stock. This rating also indicates that the analysts believe the stock will increase in price shortly. Only one of the research experts surveyed has suggested that shareholders hold on to their existing holdings, while seven others have suggested that investors purchase the company. The vast majority of market analysts who have covered the company in the preceding year have projected that the stock’s price will hit $79 per share within the next year. This price target was established.

GMED has obtained feedback from a variety of brokerages on its performance. The price target that Morgan Stanley has set for Globus Medical has increased from $60.00 to $70.00, as stated in a research note published on Friday, January 6. Additionally, an “equal weight” rating was given to the stock by the company. Wells Fargo & Company upgraded their price target for the stock of Globus Medical from $74.00 to $82.00 and gave the stock an “overweight” rating in a report released on December 12. The report was published on the same day. In addition to this, the company increased its target price for the stock. Trust Financial reaffirmed its “buy” rating on shares of Globus Medical Corporation and increased its price objective for the business in a research report that was made public on December 20. On Wednesday, October 12, Jefferies Financial Group announced the release of a study; this marked the first time they had included Globus Medical in one of their publications. They suggested that investors “buy” the stock and establish a price objective of $75.00 per share. Barclays increased their price objective for Globus Medical from $70.00 to $82.00 in a research report that was made public on Wednesday, January 4. The final and most significant adjustment was made here.

SVP Kelly Huller is reported to have sold 7,500 shares of Globus Medical stock on December 1, according to information regarding the company that was obtained from other connected sources. The stock sale resulted in an average price of $75 per share, which brought the sale to $562,500. Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail. Individuals employed by the company own a total of 24.41% of the company’s shares.

In recent weeks, several hedge funds and institutional investors have adjusted the percentage of their holdings invested in GMED. Financial Gravity Asset Management Inc. initiated a new investment in the form of approximately 197,000 dollars worth of stock in Globus Medical during the third quarter of the fiscal year. Conservest Capital Advisors Inc. increased the percentage of Globus Medical shares it owned by 2.3% during the second quarter. Conservest Capital Advisors Inc. now holds 9,587 shares of the medical device company’s stock after purchasing an additional 211 shares during the most recent quarter. The stock is currently valued at $538,000, and the company has a market cap of $537,000 as of this writing. During the second quarter, Securian Asset Management Inc. raised the amount of Globus Medical stock owned by 3.1%, bringing its total holdings of the company’s stock to 100%. Securian Asset Management Inc. now has 7,229 shares of the medical device company’s stock, worth a combined total of $406,000 after purchasing an additional 214 shares during the most recent quarter. During the third quarter, Captrust Financial Advisors increased the amount of Globus Medical stock owned by 0.8%, bringing its total ownership percentage to 100%. After making an additional purchase of 227 shares during the most recent fiscal quarter, Captrust Financial Advisors now owns a total of 28,776 stock held by the medical device company. The current value of these shares, when traded on the market, is $1,714,000. Finally, during the second quarter of the fiscal year, Synovus Financial Corp. increased the percentage of Globus Medical in which it is invested by 2.1%. The value of the stock holdings that Synovus Financial Corp. has in the medical device company has increased to $688,000 due to the company’s acquisition of an additional 250 shares, bringing the total number of shares it owns to 12,271. Institutional investors and hedge funds hold 74% and 3% of the total number of shares issued by the company, respectively.

When trading began on Wednesday, the price of a single share of NYSE GMED stock was $72.91. Globus Medical reached an all-time high price of $81.78 within the last 52 weeks, while the company’s all-time low price was $52.60. A price-to-earnings ratio of 48.29, a price-to-earnings-growth ratio of 2.85, and a beta value of 1.02 are all characteristics of the company in question. The company’s total value, as represented by its market capitalization, is $7.28 billion. The stock’s simple moving average over the past 200 days is $64.98, and its simple moving average over the past 50 days is $72.11.

Tuesday, November 8, saw the release of the most recent quarterly financial report that can be found for Globus Medical (NYSE: GMED). The manufacturer of medical devices reported earnings per share for the quarter of $0.50, which fell short of the $0.52 that market analysts had anticipated earning for the quarter. The revenue for the quarter came in significantly higher than the $252.94 million analysts had anticipated, coming in at $254.15 million instead. Globus Medical had a net margin of 15.55 percent and an equity return rate of 11.59 percent as of the end of the year. Analysts on the sell side anticipate that Globus Medical will report earnings of 2.03 cents per share for the current fiscal year.

People in the United States and other countries who suffer from musculoskeletal conditions are the target demographic for the healthcare products developed and distributed by Globus Medical, Inc., a medical device company. It offers standard fusion implants and other spine goods for treating degenerative, deformative, tumor, and trauma diseases, such as intervertebral spacers, plating systems, and corpectomy devices. It’s possible that several different things are to blame for these conditions. In addition to this, it offers alternative methods of interventional pain management for the treatment of spinal compression fractures and therapy options for motion preservation technologies such as dynamic stabilization, complete disc replacement, and interspinous distraction devices. All of these are included in the treatment plan.


Leave a comment

Your email address will not be published. Required fields are marked *